Display options
Cite
Rejnmark L, Vestergaard P, Heickendorff L, et al. Simvastatin does not affect vitamin d status, but low vitamin d levels are associated with dyslipidemia: results from a randomised, controlled trial. Int J Endocrinol. 2009;2010:957174doi: 10.1155/2010/957174.
Rejnmark, L., Vestergaard, P., Heickendorff, L., & Mosekilde, L. (2010). Simvastatin does not affect vitamin d status, but low vitamin d levels are associated with dyslipidemia: results from a randomised, controlled trial. International journal of endocrinology, 2010957174. https://doi.org/10.1155/2010/957174
Rejnmark, Lars, et al. "Simvastatin does not affect vitamin d status, but low vitamin d levels are associated with dyslipidemia: results from a randomised, controlled trial." International journal of endocrinology vol. 2010 (2010): 957174. doi: https://doi.org/10.1155/2010/957174
Rejnmark L, Vestergaard P, Heickendorff L, Mosekilde L. Simvastatin does not affect vitamin d status, but low vitamin d levels are associated with dyslipidemia: results from a randomised, controlled trial. Int J Endocrinol. 2010;2010:957174. doi: 10.1155/2010/957174. Epub 2009 Jul 21. PMID: 20016680; PMCID: PMC2778175.
Copy Download .nbib Format: NLM
Share it on

Int J Endocrinol. 2010;2010:957174. doi: 10.1155/2010/957174. Epub 2009 Jul 21.

Simvastatin does not affect vitamin d status, but low vitamin d levels are associated with dyslipidemia: results from a randomised, controlled trial.

International journal of endocrinology

Lars Rejnmark, Peter Vestergaard, Lene Heickendorff, Leif Mosekilde

Affiliations

  1. Department of Endocrinology and Metabolism C, Aarhus Sygehus, Aarhus University Hospital, 8000 Aarhus, Denmark.

PMID: 20016680 PMCID: PMC2778175 DOI: 10.1155/2010/957174

Abstract

Objectives. Statin drugs act as inhibitors of the 3-hydroxy-3methylglutaryl coenzyme A (HMG-CoA) reductase enzyme early in the mevalonate pathway, thereby reducing the endogenous cholesterol synthesis. In recent studies, it has been suggested from epidemiological data that statins also may improve vitamin D status, as measured by increased plasma 25-hydroxyvitamin D (25OHD) levels. We now report the results from a randomised controlled trial on effects of simvastatin on plasma 25OHD levels. Design and Methods. We randomised 82 healthy postmenopausal women to one year of treatment with either simvastatin 40 mg/d or placebo and performed measurement at baseline and after 26 and 52 weeks of treatment. The study was completed by 77 subjects. Results. Compared with placebo, plasma levels of cholesterol and low-density lipoproteins decreased in response to treatment with simvastatin, but our study showed no effect of simvastatin on vitamin D status. However, plasma levels of triglycerides were inversely associated with tertiles of plasma 25OHD levels and changes in plasma triglycerides levels correlated inversely with seasonal changes in vitamin D status. Conclusion. Our data do not support a pharmacological effect of statins on vitamin D status, but do suggest that vitamin D may influence plasma lipid profile and thus be of importance to cardiovascular health.

References

  1. J Endocrinol Invest. 2003 Aug;26(8):748-53 - PubMed
  2. Int J Epidemiol. 1990 Sep;19(3):559-63 - PubMed
  3. Curr Atheroscler Rep. 2007 Aug;9(2):110-5 - PubMed
  4. J Vasc Res. 2007;44(1):11-8 - PubMed
  5. Lancet. 2000 Jun 24;355(9222):2218-9 - PubMed
  6. Arch Intern Med. 2008 Aug 11;168(15):1629-37 - PubMed
  7. Cas Lek Cesk. 1989 Sep 29;128(40):1254-6 - PubMed
  8. Kidney Int. 1998 May;53(5):1353-7 - PubMed
  9. Science. 1999 Dec 3;286(5446):1946-9 - PubMed
  10. J Am Soc Nephrol. 1999 Oct;10(10):2158-64 - PubMed
  11. Arch Intern Med. 2004 Jan 26;164(2):146-52 - PubMed
  12. Am J Cardiol. 2007 Oct 15;100(8):1329 - PubMed
  13. Cas Lek Cesk. 1994 Dec 5;133(23):727-9 - PubMed
  14. Osteoporos Int. 2004 Jun;15(6):452-8 - PubMed
  15. Arch Intern Med. 2007 Jun 11;167(11):1159-65 - PubMed
  16. JAMA. 2001 Apr 11;285(14):1850-5 - PubMed
  17. Arch Intern Med. 2008 Jun 9;168(11):1174-80 - PubMed
  18. Clin Chem. 2005 Sep;51(9):1683-90 - PubMed
  19. Clin Ther. 1994 Sep-Oct;16(5):824-9 - PubMed
  20. J Steroid Biochem Mol Biol. 2004 May;89-90(1-5):387-92 - PubMed
  21. Am J Cardiol. 2007 Apr 1;99(7):903-5 - PubMed
  22. Osteoporos Int. 2005 Aug;16(8):990-8 - PubMed
  23. Calcif Tissue Int. 2006 Jul;79(1):27-36 - PubMed
  24. Lancet. 1998 Aug 29;352(9129):709-10 - PubMed
  25. J Clin Endocrinol Metab. 2007 Dec;92(12):4671-7 - PubMed
  26. Atherosclerosis. 1970 Sep-Oct;12(2):313-7 - PubMed
  27. J Clin Invest. 1989 Jun;83(6):1903-15 - PubMed
  28. N Engl J Med. 2007 Jul 19;357(3):266-81 - PubMed
  29. J Bone Miner Res. 2004 May;19(5):737-44 - PubMed
  30. Metabolism. 1991 May;40(5):524-8 - PubMed
  31. Metabolism. 2004 Jun;53(6):744-8 - PubMed
  32. J Natl Cancer Inst. 2008 Jan 16;100(2):134-9 - PubMed
  33. Clin Ther. 1990 Sep-Oct;12(5):427-30 - PubMed
  34. J Bone Miner Res. 2003 Jan;18(1):88-96 - PubMed
  35. Eur Rev Med Pharmacol Sci. 2008 Mar-Apr;12(2):83-8 - PubMed
  36. Eur J Clin Invest. 2002 Aug;32(8):581-9 - PubMed
  37. Am J Physiol. 1997 Apr;272(4 Pt 2):H1751-8 - PubMed
  38. Maturitas. 1995 Jun;22(1):55-61 - PubMed

Publication Types